Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
protein degradation
Biotech
J&J, Google venture arms line up to back EpiBiologics' series B
Protein degradation biotech EpiBiologics brought in $107 million in a series B round headed up by J&J's and Google's respective venture arms.
James Waldron
Jan 8, 2026 9:05am
Amgen weaves in UK biotech with up to $840M acquisition
Jan 6, 2026 10:35am
Amphista's targeted glue sticks the landing in early AML test
Dec 8, 2025 7:40am
Nurix trims staff as trial for lead BTK degrader kicks off
Nov 21, 2025 5:05am
AbbVie-partnered protein degrader specialist Plexium raises $60M
Aug 28, 2025 12:52pm
Plexium cuts staff, realigns resources to support pipeline
Jun 3, 2025 4:12pm
